AFH TEST ACTUAL EXAM 2026/2027 - 100%
VERIFIED QUESTIONS WITH PASSED ANSWERS &
RATIONALES - PASS GUARANTEED - A+ GRADED
179 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Demonstrate mastery of core concepts
2 AFH Test Actual Exam 2026
3 2027
4 100% Verified Questions with Passed Answers & Rationales
5 Pass Guaranteed
6 A+ Graded
7 Foundations of AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers &
Rationales - Pass Guaranteed - A+ Graded
8 Applied AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers & Rationales -
Pass Guaranteed - A+ Graded
9 Advanced AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers &
Rationales - Pass Guaranteed - A+ Graded
10 AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers & Rationales - Pass
Guaranteed - A+ Graded Review
Page 1
,Q1 DEMONSTRATE MASTERY OF CORE CONCEPTS
A 58-year-old with new-onset atrial fibrillation and a CHA2DS2-VASc score of 3 is
prescribed apixaban. Which pharmacogenetic consideration is most critical for
dosing?
A. CYP3A4 and P-glycoprotein inhibitor coadministration requires dose reduction regardless of
renal function. CORRECT
B. CYP2C9 and VKORC1 polymorphisms determine the therapeutic window.
C. SLCO1B1 genotype affects hepatic uptake and clearance of apixaban.
D. Factor V Leiden mutation necessitates a higher apixaban dose.
RATIONALE: Apixaban is a substrate of CYP3A4 and P-gp; strong inhibitors (e.g., ketoconazole)
mandate dose reduction. CYP2C9/VKORC1 affect warfarin, not apixaban. SLCO1B1 is relevant
to statins, and Factor V Leiden does not alter apixaban dosing.
Q2 DEMONSTRATE MASTERY OF CORE CONCEPTS
In a patient with suspected heparin-induced thrombocytopenia, which laboratory
finding most reliably supports the diagnosis despite a positive PF4/heparin
ELISA?
A. Elevated D-dimer and prolonged PT
B. Positive serotonin release assay with >50% release at 0.1 U/mL heparin CORRECT
C. Thrombocytopenia with platelet count <20,000/µL and bleeding
D. Presence of lupus anticoagulant
RATIONALE: The serotonin release assay is the functional gold standard; >50% release at low
heparin confirms HIT. D-dimer/PT are nonspecific. Severe thrombocytopenia with bleeding is
atypical (HIT is thrombotic). Lupus anticoagulant can cause false-positive ELISA but not confirm
HIT.
Page 2
,Q3 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which statement best distinguishes the mechanism of action of direct oral
anticoagulants (DOACs) from vitamin K antagonists?
A. DOACs inhibit activated clotting factors directly, while warfarin reduces synthesis of multiple
factors. CORRECT
B. DOACs enhance antithrombin III activity, while warfarin inhibits factor Xa.
C. DOACs are irreversible inhibitors of thrombin only, while warfarin blocks vitamin K epoxide
reductase.
D. DOACs require antithrombin for activity, while warfarin acts on the extrinsic pathway.
RATIONALE: DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) directly inhibit thrombin or
factor Xa. Warfarin inhibits VKORC1, reducing factors II, VII, IX, X. DOACs do not require
antithrombin; dabigatran is reversible; warfarin does not directly inhibit factor Xa.
Q4 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient on warfarin for mechanical mitral valve presents with an INR of 5.2 and
minor bleeding. Which management is most appropriate?
A. Hold warfarin, give vitamin K 5 mg orally, and recheck INR in 24 hours. CORRECT
B. Administer 4-factor prothrombin complex concentrate (PCC) immediately.
C. Give fresh frozen plasma (FFP) 15 mL/kg and resume warfarin at a lower dose.
D. Administer vitamin K 10 mg IV and repeat INR in 6 hours.
RATIONALE: For INR >4.5 with minor bleeding, guidelines recommend holding warfarin and oral
vitamin K (2.5-5 mg). PCC is for life-threatening bleeding. FFP is less effective and not first-line.
IV vitamin K 10 mg is excessive and may cause anaphylaxis; also, mechanical valves require
bridging if warfarin held, but here holding and low-dose vitamin K is appropriate.
Page 3
, Q5 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the role of anti-Xa activity monitoring in
patients receiving enoxaparin?
A. Routine monitoring is required in all patients to ensure therapeutic efficacy.
B. Monitoring is indicated in pregnancy, renal impairment, obesity, and extremes of body weight.
CORRECT
C. Anti-Xa levels are used to adjust warfarin dosing in bridging therapy.
D. Anti-Xa monitoring is only useful for unfractionated heparin, not LMWH.
RATIONALE: Routine monitoring is not needed for LMWH due to predictable pharmacokinetics.
However, special populations (pregnancy, renal impairment, obesity, pediatric) may require
anti-Xa monitoring. Anti-Xa does not guide warfarin dosing. It is also used for LMWH, not just
UFH.
Q6 DEMONSTRATE MASTERY OF CORE CONCEPTS
For a patient with acute pulmonary embolism and hemodynamic instability, which
reperfusion therapy is first-line?
A. Catheter-directed thrombolysis with low-dose alteplase
B. Systemic intravenous thrombolysis with alteplase 100 mg over 2 hours CORRECT
C. Surgical embolectomy
D. Anticoagulation with unfractionated heparin alone
RATIONALE: High-risk PE with shock mandates systemic thrombolysis unless contraindicated.
Catheter-directed thrombolysis is for intermediate-risk. Surgical embolectomy is reserved when
thrombolysis fails or is contraindicated. Anticoagulation alone is insufficient for unstable patients.
Page 4
VERIFIED QUESTIONS WITH PASSED ANSWERS &
RATIONALES - PASS GUARANTEED - A+ GRADED
179 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Demonstrate mastery of core concepts
2 AFH Test Actual Exam 2026
3 2027
4 100% Verified Questions with Passed Answers & Rationales
5 Pass Guaranteed
6 A+ Graded
7 Foundations of AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers &
Rationales - Pass Guaranteed - A+ Graded
8 Applied AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers & Rationales -
Pass Guaranteed - A+ Graded
9 Advanced AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers &
Rationales - Pass Guaranteed - A+ Graded
10 AFH Test Actual Exam 2026/2027 - 100% Verified Questions with Passed Answers & Rationales - Pass
Guaranteed - A+ Graded Review
Page 1
,Q1 DEMONSTRATE MASTERY OF CORE CONCEPTS
A 58-year-old with new-onset atrial fibrillation and a CHA2DS2-VASc score of 3 is
prescribed apixaban. Which pharmacogenetic consideration is most critical for
dosing?
A. CYP3A4 and P-glycoprotein inhibitor coadministration requires dose reduction regardless of
renal function. CORRECT
B. CYP2C9 and VKORC1 polymorphisms determine the therapeutic window.
C. SLCO1B1 genotype affects hepatic uptake and clearance of apixaban.
D. Factor V Leiden mutation necessitates a higher apixaban dose.
RATIONALE: Apixaban is a substrate of CYP3A4 and P-gp; strong inhibitors (e.g., ketoconazole)
mandate dose reduction. CYP2C9/VKORC1 affect warfarin, not apixaban. SLCO1B1 is relevant
to statins, and Factor V Leiden does not alter apixaban dosing.
Q2 DEMONSTRATE MASTERY OF CORE CONCEPTS
In a patient with suspected heparin-induced thrombocytopenia, which laboratory
finding most reliably supports the diagnosis despite a positive PF4/heparin
ELISA?
A. Elevated D-dimer and prolonged PT
B. Positive serotonin release assay with >50% release at 0.1 U/mL heparin CORRECT
C. Thrombocytopenia with platelet count <20,000/µL and bleeding
D. Presence of lupus anticoagulant
RATIONALE: The serotonin release assay is the functional gold standard; >50% release at low
heparin confirms HIT. D-dimer/PT are nonspecific. Severe thrombocytopenia with bleeding is
atypical (HIT is thrombotic). Lupus anticoagulant can cause false-positive ELISA but not confirm
HIT.
Page 2
,Q3 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which statement best distinguishes the mechanism of action of direct oral
anticoagulants (DOACs) from vitamin K antagonists?
A. DOACs inhibit activated clotting factors directly, while warfarin reduces synthesis of multiple
factors. CORRECT
B. DOACs enhance antithrombin III activity, while warfarin inhibits factor Xa.
C. DOACs are irreversible inhibitors of thrombin only, while warfarin blocks vitamin K epoxide
reductase.
D. DOACs require antithrombin for activity, while warfarin acts on the extrinsic pathway.
RATIONALE: DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) directly inhibit thrombin or
factor Xa. Warfarin inhibits VKORC1, reducing factors II, VII, IX, X. DOACs do not require
antithrombin; dabigatran is reversible; warfarin does not directly inhibit factor Xa.
Q4 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient on warfarin for mechanical mitral valve presents with an INR of 5.2 and
minor bleeding. Which management is most appropriate?
A. Hold warfarin, give vitamin K 5 mg orally, and recheck INR in 24 hours. CORRECT
B. Administer 4-factor prothrombin complex concentrate (PCC) immediately.
C. Give fresh frozen plasma (FFP) 15 mL/kg and resume warfarin at a lower dose.
D. Administer vitamin K 10 mg IV and repeat INR in 6 hours.
RATIONALE: For INR >4.5 with minor bleeding, guidelines recommend holding warfarin and oral
vitamin K (2.5-5 mg). PCC is for life-threatening bleeding. FFP is less effective and not first-line.
IV vitamin K 10 mg is excessive and may cause anaphylaxis; also, mechanical valves require
bridging if warfarin held, but here holding and low-dose vitamin K is appropriate.
Page 3
, Q5 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the role of anti-Xa activity monitoring in
patients receiving enoxaparin?
A. Routine monitoring is required in all patients to ensure therapeutic efficacy.
B. Monitoring is indicated in pregnancy, renal impairment, obesity, and extremes of body weight.
CORRECT
C. Anti-Xa levels are used to adjust warfarin dosing in bridging therapy.
D. Anti-Xa monitoring is only useful for unfractionated heparin, not LMWH.
RATIONALE: Routine monitoring is not needed for LMWH due to predictable pharmacokinetics.
However, special populations (pregnancy, renal impairment, obesity, pediatric) may require
anti-Xa monitoring. Anti-Xa does not guide warfarin dosing. It is also used for LMWH, not just
UFH.
Q6 DEMONSTRATE MASTERY OF CORE CONCEPTS
For a patient with acute pulmonary embolism and hemodynamic instability, which
reperfusion therapy is first-line?
A. Catheter-directed thrombolysis with low-dose alteplase
B. Systemic intravenous thrombolysis with alteplase 100 mg over 2 hours CORRECT
C. Surgical embolectomy
D. Anticoagulation with unfractionated heparin alone
RATIONALE: High-risk PE with shock mandates systemic thrombolysis unless contraindicated.
Catheter-directed thrombolysis is for intermediate-risk. Surgical embolectomy is reserved when
thrombolysis fails or is contraindicated. Anticoagulation alone is insufficient for unstable patients.
Page 4
